Advances in the Management of HPV-Related Oropharyngeal Cancer

• Published in: Journal of oncology Vol. 2019; no. 2019; pp. 1 - 8
• Main Authors: Polimeni, A., Mezi, S., de Vincentiis, M., Valentini, V., Tombolini, V., De Felice, Francesca, Brugnoletti, O.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2019; Hindawi; Hindawi Limited
• Subjects: Alcohol; Cancer therapies; Chemotherapy; Classification; Collaboration; Cyclin-dependent kinases; Drug dosages; Head & neck cancer; Human papillomavirus; Lymphatic system; Medical prognosis; Oncology; Patients; Quality of life; Radiation therapy; Review; Surgery; Throat cancer
• ISSN: 1687-8450; 1687-8450; 1687-8469
• DOI: 10.1155/2019/9173729

Patients with human papillomavirus- (HPV-) related oropharyngeal squamous cell carcinoma (OPSCC) have a better prognosis than HPV-negative OPSCC when treated with standard high-dose cisplatin-based chemoradiotherapy. Consistent with this assertion and due to younger age at diagnosis, novel approaches to minimize treatment sequelae while preserving survival outcomes become of paramount importance. Here, we critically reviewed the evidence-based literature supporting the deintensification strategies in HPV-related OPSCC management, including radiotherapy dose and/or volume reduction, replacement of cisplatin radiosensitising chemotherapy, and the use of transoral surgery. Undoubtedly, further researches are needed before changing the standard of care in this setting of patients.